Pamela Klein
InvestorFounder and Principal, PMK BioResearch at Ysios Capital
San Francisco, California, United States
About
Dr. Pamela M. Klein is founder and principal of PMK BioResearch, providing advisory and strategic consulting to the biotechnology industry, and serves as consulting Chief Medical Officer of Olema Oncology. She previously held Chief Medical Officer roles at several biotech companies, including Intellikine (acquired by Takeda), and worked at Genentech from 2001 to 2008, ending as Vice President of Development where she oversaw development of drugs such as trastuzumab, rituximab, pertuzumab and erlotinib. She earlier co-founded and served as research director for the National Cancer Institute–Navy Breast Care Center, holds a biology degree from California State University Northridge and a medical degree from Loyola University Chicago's Stritch School of Medicine, and trained in internal medicine and medical oncology.
Invests in
Biotech
Experience
- argenxIndependent Director; Board Of Directorscurrent2016 — presentThe Netherlands
- Frontier MedicinesIndependent Director; Board of Directorscurrent2023 — presentSouth San Francisco, California, United States
- ONA TherapeuticsIndependent Director, Board of Directorscurrent2023 — presentBarcelona, Catalonia, Spain
- Ysios CapitalVenture Partnercurrent2023 — presentBarcelona, Catalonia, Spain
- ShasqiBoard Director, Independentcurrent2023 — present
- PMK BioResearchOncologist - Independent Biotech/Pharma Consultant/Drug Development Strategycurrent2008 — present
- Patrys LimitedIndependent Director; Board Of Directors2019 — 2025Australia
- I-Mab BiopharmaInterim Chairperson, Board of Directors2024
- I-Mab BiopharmaIndependent Director; Board of Directors2020 — 2024United States; China
- F-star Therapeutics, Inc.Member, Board of Directors2020 — 2023United Kingdom
- Sardona TherapeuticsIndependent Director; Board of Directors2023San Francisco Bay Area
- Olema OncologyChief Medical Officer2019 — 2022San Francisco
- Spring Bank Pharmaceuticals, Inc.Member, Board of Directors2019 — 2020Massachusetts, United States
- Intellikine IncChief Medical Officer2008 — 2011
- GenentechVice President, Clinical Development, Oncology2001 — 2007
- National Cancer InstituteResearch Director, NCI-Navy Breast Center1995 — 2001
Education
- Loyola University Chicago Stritch School of MedicineM.D., Oncology1988 — 1992
- California State University, NorthridgeBachelor's degree, Biology
Skills & more
+12 more
BiomarkersLifesciencesMolecular BiologyPharmaceutical IndustryImmunologyInfectious DiseasesTranslational ResearchHematologyMedical AffairsINDPharmacologyAssay DevelopmentFrom Pamela's professional profile.
Same school
Also attended Loyola University Chicago Stritch School of Medicine2
Also attended California State University, Northridge18
+ 12 more
Shared employers
Also worked at Frontier Medicines2
Also worked at ONA Therapeutics5
Also worked at Patrys Limited1
Also worked at F-star Therapeutics, Inc.6
Investments
Board seats
ArgenxF-Star TherapeuticsI-Mab BiopharmaJiya Acquisition CorporationPatrys
Per the firm's website.

.png)



























